Downloadable Slides From Novel Strategies in ER-Positive Breast Cancer: An Evolving Cascade of Treatments for Long-Term Disease Control
prIME Downloadable Slides
prIME Downloadable Slides

Downloadable Slides From Novel Strategies in ER-Positive Breast Cancer: An Evolving Cascade of Treatments for Long-Term Disease Control

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Expand your understanding of the growing treatment options for estrogen receptor (ER)—positive breast cancer. These downloadable slides, presented at the 2017 Breast Cancer Conference in Brussels, will build on your knowledge of ER+ breast cancer, important molecular pathways associated with endocrine sensitivity and resistance, and novel agents involved in cell cycle inhibition.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

May 8, 2017

Expiration Date

May 8, 2018

Featured Expert

  • Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Featured Topic

Endocrine sensitivity and resistance: Are we close to solving the mystery?

Featured Expert

  • Angelo Di Leo, MD, PhD, Istituto Toscano Tumori, Hospital of Prato, Prato, Italy

Featured Topic

Taking the foot off the gas: Clinical consequences of cell cycle inhibition in ER-positive metastatic breast cancer

Featured Expert

  • Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France

Featured Topic

Signaling pathway inhibition for ER-positive advanced breast cancer: New targets making a difference

Featured Expert

  • Martine Piccart, MD, PhD, Jules Bordet Institute, Brussels, Belgium

Featured Topic

The times they are a changin’: New opportunities to improve outcomes in ER-positive advanced breast cancer

Featured Expert

  • Martine Piccart, MD, PhD, Jules Bordet Institute, Brussels, Belgium

Featured Topic

prIME Points™

After successful completion of this educational activity, participants should be able to:

  • Explain the key mechanisms of endocrine resistance and the emerging strategies to enhance sensitivity to endocrine therapy
  • Examine the role of emerging biomarkers used to inform targeted treatment selection
  • Summarize the clinical application of novel combinations of targeted agents for ER-positive disease
  • Describe the optimum sequence of endocrine therapy approaches across different clinical scenarios

This educational activity is supported by a grant from Novartis Oncology.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.